Banophen's generic name is phenylbutazone, a nonsteroidal anti-inflammatory drug (NSAID) historically used to treat pain and inflammation in animals and humans. It is no longer approved for human use in the United States due to serious safety risks.
Phenylbutazone was first synthesized in the 1940s and became widely used in veterinary medicine for treating lameness in horses and other large animals. Its potency in reducing fever, pain, and swelling led to early off-label use in humans, particularly for rheumatoid arthritis and ankylosing spondylitis. However, it was withdrawn from the U.S. human market in 1977 after reports linked it to severe blood disorders, including aplastic anemia and agranulocytosis.
The drug remains available in some countries under strict regulatory control, but in the U.S., it is classified as a restricted-use veterinary drug. Its use in food-producing animals is banned in many regions due to concerns about residue transfer to consumers. Regulatory agencies such as the FDA and EMA have consistently emphasized that the risk of life-threatening hematologic side effects outweighs any therapeutic benefit in humans.
Phenylbutazone inhibits cyclooxygenase (COX) enzymes, which are responsible for producing prostaglandins-chemicals involved in inflammation, pain, and fever. By blocking COX-1 and COX-2, it reduces inflammatory responses. This mechanism is similar to other NSAIDs like ibuprofen and naproxen, but phenylbutazone is more potent and carries higher toxicity.
Unlike most NSAIDs, phenylbutazone also interferes with immune cell function and alters bone marrow activity. This contributes to its rare but fatal side effects. The drug's long half-life-up to 60 hours-means it accumulates in the body with repeated dosing, increasing the risk of adverse events even at low doses.
A 1978 study published in the New England Journal of Medicine documented 11 cases of aplastic anemia among patients treated with phenylbutazone, leading to its removal from the U.S. market. The FDA cited a 1 in 1,000 incidence rate of severe blood dyscrasias, a threshold deemed unacceptable for any drug intended for chronic conditions.
Phenylbutazone exists only as a generic formulation. There are no brand-name versions marketed in the U.S. for human use. In veterinary medicine, it is sold under various trade names, including Butazolidin, Banamine (though Banamine is actually flunixin meglumine, a different drug), and others depending on region.
| Type | Form | Use | Regulatory Status (U.S.) |
|---|---|---|---|
| Phenylbutazone (generic) | Powder, tablets, injectable solution | Veterinary: equine lameness, musculoskeletal pain | Approved for animal use only; banned in food animals |
| Butazolidin (brand) | Tablets | Veterinary: pain and inflammation in horses | Available in select countries; not FDA-approved for human use |
Despite being a generic drug, phenylbutazone is not interchangeable with other NSAIDs. Its unique pharmacokinetics and high toxicity profile make it unsuitable for substitution in clinical practice. Patients prescribed other NSAIDs should not assume phenylbutazone offers equivalent relief.
Many people confuse Banophen with other anti-inflammatory drugs due to similar-sounding names or overlapping indications. For example, Banamine is a brand name for flunixin meglumine, a different NSAID used in livestock. Flunixin is not chemically related to phenylbutazone and has a lower risk profile, though it still carries gastrointestinal and renal side effect warnings.
Another frequent error is assuming that "generic" means "safe." Phenylbutazone is a generic drug, but its safety record is among the worst in the NSAID class. The term "generic" refers only to chemical equivalence, not safety or efficacy. A 2020 review in the Journal of Clinical Pharmacology confirmed that generic drugs must meet bioequivalence standards but do not undergo additional safety testing beyond what the original branded version underwent.
There is no known human use for phenylbutazone today. Any online reference suggesting it is available for arthritis or joint pain in humans is misleading or outdated. The FDA maintains a public database listing all approved drugs, and phenylbutazone does not appear in the human drug list.
In 1976, a 45-year-old man with severe rheumatoid arthritis was prescribed phenylbutazone after failing to respond to aspirin and corticosteroids. He took 100 mg twice daily for six weeks. After four weeks, he developed fatigue, fever, and bruising. Blood tests revealed a platelet count of 15,000/μL (normal: 150,000-450,000) and hemoglobin of 7 g/dL (normal: 13.5-17.5). He was diagnosed with agranulocytosis and required hospitalization, platelet transfusions, and bone marrow biopsy. Recovery took over three months, and he remains at risk for recurrence.
This case illustrates why phenylbutazone is no longer used in human medicine. Even short-term use can trigger irreversible hematologic damage. The risk is dose-dependent and cumulative. The FDA advises against any use in humans, regardless of indication.
If you or someone you know has taken phenylbutazone within the past two weeks, seek medical evaluation immediately. Symptoms of blood disorders include unexplained bruising, prolonged bleeding, fever, sore throat, and fatigue. These signs may indicate early onset of agranulocytosis or aplastic anemia.
For those managing chronic pain, safer alternatives exist. Nonsteroidal anti-inflammatory drugs like celecoxib or naproxen are better tolerated and carry lower risk profiles. Antidepressants such as duloxetine are effective for neuropathic pain. Offloading aripiprazole or other psychiatric medications may be relevant if mood-related factors contribute to pain perception.
Phenylbutazone remains a cautionary tale in pharmacology. Its history underscores the importance of balancing therapeutic benefit against potential harm. Today, it shows that even well-known drugs can pose unacceptable risks when used inappropriately.